Spectrum Pharmaceuticals to Present Corporate Update at Stifel Nicolaus Healthcare Conference in Boston on September 6th and at BioCentury NewsMakers Conference in New York City on September 7th
<0> Spectrum PharmaceuticalsShiv Kapoor, 702-835-6300Vice President, Strategic Planning & Investor Relations </0>
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company’s business strategy and commercial and development-stage programs will be given at the Stifel Nicolaus Healthcare Conference being held at The Four Seasons Hotel in Boston. The Company presentation is on Thursday, September 06, 2012, at 4:25 PM ET.
Spectrum also will be presenting at BioCentury’s 19th Annual NewsMakers in the Biotech Industry Conference being held at the Millennium Broadway Hotel & Conference Center in New York City. The Company presentation is on Friday, September 7th at 10:00 AM ET.
Live webcasts of Spectrum's corporate presentations will be available at .
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in oncology and hematology. Spectrum currently markets two oncology drugs ─ FUSILEV® (levoleucovorin) for Injection in the U.S. and ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use, for which the Company has worldwide marketing rights. Spectrum's strong track record in in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at .